JP2001526220A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001526220A5 JP2001526220A5 JP2000525097A JP2000525097A JP2001526220A5 JP 2001526220 A5 JP2001526220 A5 JP 2001526220A5 JP 2000525097 A JP2000525097 A JP 2000525097A JP 2000525097 A JP2000525097 A JP 2000525097A JP 2001526220 A5 JP2001526220 A5 JP 2001526220A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- urea
- butyl
- group
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006467 substitution reaction Methods 0.000 description 182
- 125000003118 aryl group Chemical group 0.000 description 121
- 229910052736 halogen Inorganic materials 0.000 description 105
- 150000002367 halogens Chemical class 0.000 description 105
- -1 1-methyl-3-tert-butyl-5-pyrazolyl Chemical group 0.000 description 56
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 55
- 239000004202 carbamide Substances 0.000 description 55
- 150000001875 compounds Chemical class 0.000 description 54
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 46
- 125000000753 cycloalkyl group Chemical group 0.000 description 38
- 125000004076 pyridyl group Chemical group 0.000 description 38
- 125000000217 alkyl group Chemical group 0.000 description 28
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- 229910052739 hydrogen Inorganic materials 0.000 description 22
- 239000001257 hydrogen Substances 0.000 description 21
- 125000001424 substituent group Chemical group 0.000 description 21
- 125000002877 alkyl aryl group Chemical group 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- 229910052760 oxygen Inorganic materials 0.000 description 20
- 229910052717 sulfur Chemical group 0.000 description 20
- 150000002431 hydrogen Chemical class 0.000 description 18
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 18
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 16
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000001301 oxygen Chemical group 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 239000011593 sulfur Chemical group 0.000 description 10
- 125000002950 monocyclic group Chemical group 0.000 description 8
- 125000001624 naphthyl group Chemical group 0.000 description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- MQQZEXCPOASVFI-UHFFFAOYSA-N 1-(5-tert-butyl-1h-pyrazol-3-yl)-3-(3-pyridin-4-ylsulfanylphenyl)urea Chemical compound N1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(SC=2C=CN=CC=2)=C1 MQQZEXCPOASVFI-UHFFFAOYSA-N 0.000 description 4
- UDYOWLBACWDBNL-UHFFFAOYSA-N 1-(5-tert-butyl-1h-pyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound N1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 UDYOWLBACWDBNL-UHFFFAOYSA-N 0.000 description 4
- NISMKTLRQBAMPS-UHFFFAOYSA-N 1-(5-tert-butyl-1h-pyrazol-3-yl)-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound N1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(SC=3C=CN=CC=3)=CC=2)=N1 NISMKTLRQBAMPS-UHFFFAOYSA-N 0.000 description 4
- NIQFSOWYCXNLNI-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(3-pyridin-4-ylsulfanylphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(SC=2C=CN=CC=2)=C1 NIQFSOWYCXNLNI-UHFFFAOYSA-N 0.000 description 4
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 4
- FDHKHZIFBOZGKU-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1SC1=CC=NC=C1 FDHKHZIFBOZGKU-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- MTTAQONWKYZSGQ-UHFFFAOYSA-N 1-(3-benzoylphenyl)-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=C(C=CC=2)C(=O)C=2C=CC=CC=2)=N1 MTTAQONWKYZSGQ-UHFFFAOYSA-N 0.000 description 2
- NNGZTFCLDJGBAR-UHFFFAOYSA-N 1-(3-propan-2-yl-1,2-oxazol-5-yl)-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1N=C(C(C)C)C=C1NC(=O)NC(C=C1)=CC=C1SC1=CC=NC=C1 NNGZTFCLDJGBAR-UHFFFAOYSA-N 0.000 description 2
- ZLRZULLSROJBLS-UHFFFAOYSA-N 1-(3-tert-butyl-1,2-oxazol-5-yl)-3-(3-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(SC=2C=CN=CC=2)=C1 ZLRZULLSROJBLS-UHFFFAOYSA-N 0.000 description 2
- ORIFMUAUSBIDGC-UHFFFAOYSA-N 1-(3-tert-butyl-1,2-oxazol-5-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 ORIFMUAUSBIDGC-UHFFFAOYSA-N 0.000 description 2
- YSOLQZIGFKVUPX-UHFFFAOYSA-N 1-(3-tert-butyl-1,2-oxazol-5-yl)-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1SC1=CC=NC=C1 YSOLQZIGFKVUPX-UHFFFAOYSA-N 0.000 description 2
- QNPSZGWMKYQMSH-UHFFFAOYSA-N 1-(3-tert-butyl-1,2-oxazol-5-yl)-3-[4-(4-methoxyphenoxy)phenyl]urea Chemical compound C1=CC(OC)=CC=C1OC(C=C1)=CC=C1NC(=O)NC1=CC(C(C)(C)C)=NO1 QNPSZGWMKYQMSH-UHFFFAOYSA-N 0.000 description 2
- KDXIBGWSUXXMBV-UHFFFAOYSA-N 1-(3-tert-butyl-1,2-oxazol-5-yl)-3-[4-(4-methylpyridin-3-yl)oxyphenyl]urea Chemical compound CC1=CC=NC=C1OC(C=C1)=CC=C1NC(=O)NC1=CC(C(C)(C)C)=NO1 KDXIBGWSUXXMBV-UHFFFAOYSA-N 0.000 description 2
- KXEOEENRCKNIJO-UHFFFAOYSA-N 1-(3-tert-butyl-1,2-oxazol-5-yl)-3-[4-(pyridin-4-ylmethyl)phenyl]urea Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1CC1=CC=NC=C1 KXEOEENRCKNIJO-UHFFFAOYSA-N 0.000 description 2
- RBTTWKACKBLWGC-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(3-pyridin-4-yloxyphenyl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=C(OC=3C=CN=CC=3)C=CC=2)=N1 RBTTWKACKBLWGC-UHFFFAOYSA-N 0.000 description 2
- BWYIEKUXLAWWDO-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(3-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=C(SC=3C=CN=CC=3)C=CC=2)=N1 BWYIEKUXLAWWDO-UHFFFAOYSA-N 0.000 description 2
- ANWRKPQVLGBTCG-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-phenoxyphenyl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 ANWRKPQVLGBTCG-UHFFFAOYSA-N 0.000 description 2
- XIGJMGPUXKZADA-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-pyridin-3-yloxyphenyl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC=3C=NC=CC=3)=CC=2)=N1 XIGJMGPUXKZADA-UHFFFAOYSA-N 0.000 description 2
- XKNAGLMNQADBQE-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC=3C=CN=CC=3)=CC=2)=N1 XKNAGLMNQADBQE-UHFFFAOYSA-N 0.000 description 2
- MBPSLEWGDKMGQY-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(SC=3C=CN=CC=3)=CC=2)=N1 MBPSLEWGDKMGQY-UHFFFAOYSA-N 0.000 description 2
- OCVLLNOZMGLZMR-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[3-(3-methylpyridin-4-yl)oxyphenyl]urea Chemical compound CC1=CN=CC=C1OC1=CC=CC(NC(=O)NC2=NOC(=C2)C(C)(C)C)=C1 OCVLLNOZMGLZMR-UHFFFAOYSA-N 0.000 description 2
- RVAHNWTXRHZRLG-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[3-(3-methylpyridin-4-yl)sulfanylphenyl]urea Chemical compound CC1=CN=CC=C1SC1=CC=CC(NC(=O)NC2=NOC(=C2)C(C)(C)C)=C1 RVAHNWTXRHZRLG-UHFFFAOYSA-N 0.000 description 2
- RQOXVIHEZQVYGS-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[3-(4-methylpyridin-3-yl)oxyphenyl]urea Chemical compound CC1=CC=NC=C1OC1=CC=CC(NC(=O)NC2=NOC(=C2)C(C)(C)C)=C1 RQOXVIHEZQVYGS-UHFFFAOYSA-N 0.000 description 2
- ZNHFSYPNHIOTRT-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(3-hydroxyphenoxy)phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC=3C=C(O)C=CC=3)=CC=2)=N1 ZNHFSYPNHIOTRT-UHFFFAOYSA-N 0.000 description 2
- VJWFZMSZAJHSFF-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(3-methylpyridin-4-yl)oxyphenyl]urea Chemical compound CC1=CN=CC=C1OC(C=C1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 VJWFZMSZAJHSFF-UHFFFAOYSA-N 0.000 description 2
- WFBGXNIMCQEGOX-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(3-methylpyridin-4-yl)sulfanylphenyl]urea Chemical compound CC1=CN=CC=C1SC(C=C1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 WFBGXNIMCQEGOX-UHFFFAOYSA-N 0.000 description 2
- DMQFIGFOGVTSFP-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(4-hydroxyphenoxy)phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC=3C=CC(O)=CC=3)=CC=2)=N1 DMQFIGFOGVTSFP-UHFFFAOYSA-N 0.000 description 2
- CJUNRHGYKDHACB-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(pyridin-4-ylmethyl)phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(CC=3C=CN=CC=3)=CC=2)=N1 CJUNRHGYKDHACB-UHFFFAOYSA-N 0.000 description 2
- PXMZWZHOSUYALM-UHFFFAOYSA-N 1-(5-tert-butyl-1h-pyrazol-3-yl)-3-(3-pyridin-4-yloxyphenyl)urea Chemical compound N1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(OC=2C=CN=CC=2)=C1 PXMZWZHOSUYALM-UHFFFAOYSA-N 0.000 description 2
- MSMDSZZGUDIFPB-UHFFFAOYSA-N 1-(5-tert-butyl-1h-pyrazol-3-yl)-3-(4-phenoxyphenyl)urea Chemical compound N1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 MSMDSZZGUDIFPB-UHFFFAOYSA-N 0.000 description 2
- VWBAHTCOVBWTMX-UHFFFAOYSA-N 1-(5-tert-butyl-1h-pyrazol-3-yl)-3-[4-(pyridin-4-ylmethyl)phenyl]urea Chemical compound N1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1CC1=CC=NC=C1 VWBAHTCOVBWTMX-UHFFFAOYSA-N 0.000 description 2
- JDKYGCYHGTVUOU-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(3-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(OC=2C=CN=CC=2)=C1 JDKYGCYHGTVUOU-UHFFFAOYSA-N 0.000 description 2
- HFVZEWHYOCNZGL-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-phenoxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 HFVZEWHYOCNZGL-UHFFFAOYSA-N 0.000 description 2
- UYYMFPJGZUWZKS-UHFFFAOYSA-N 1-(5-tert-butylthiophen-3-yl)-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound S1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(SC=3C=CN=CC=3)=CC=2)=C1 UYYMFPJGZUWZKS-UHFFFAOYSA-N 0.000 description 2
- WKAIPJMBCLQCSX-UHFFFAOYSA-N 1-(5-tert-butylthiophen-3-yl)-3-[4-(3-methylphenoxy)phenyl]urea Chemical compound CC1=CC=CC(OC=2C=CC(NC(=O)NC=3C=C(SC=3)C(C)(C)C)=CC=2)=C1 WKAIPJMBCLQCSX-UHFFFAOYSA-N 0.000 description 2
- KUMIMKXLYUJKTQ-UHFFFAOYSA-N 1-(5-tert-butylthiophen-3-yl)-3-[4-(4-hydroxyphenoxy)phenyl]urea Chemical compound S1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC=3C=CC(O)=CC=3)=CC=2)=C1 KUMIMKXLYUJKTQ-UHFFFAOYSA-N 0.000 description 2
- TXGSEPBWHRRHQE-UHFFFAOYSA-N 1-(5-tert-butylthiophen-3-yl)-3-[4-(4-methoxyphenoxy)phenyl]urea Chemical compound C1=CC(OC)=CC=C1OC(C=C1)=CC=C1NC(=O)NC1=CSC(C(C)(C)C)=C1 TXGSEPBWHRRHQE-UHFFFAOYSA-N 0.000 description 2
- RAAIQRXSFVOCHG-UHFFFAOYSA-N 1-[3-(1,3-benzothiazol-2-yloxy)phenyl]-3-(3-tert-butyl-1,2-oxazol-5-yl)urea Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(OC=2SC3=CC=CC=C3N=2)=C1 RAAIQRXSFVOCHG-UHFFFAOYSA-N 0.000 description 2
- XHWVFNIWFYIPIZ-UHFFFAOYSA-N 1-[3-(1,3-benzothiazol-2-yloxy)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=C(OC=3SC4=CC=CC=C4N=3)C=CC=2)=N1 XHWVFNIWFYIPIZ-UHFFFAOYSA-N 0.000 description 2
- RHSMGLCDPGODHW-UHFFFAOYSA-N 1-[3-(1,3-benzothiazol-2-yloxy)phenyl]-3-(5-tert-butyl-2-methylpyrazol-3-yl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(OC=2SC3=CC=CC=C3N=2)=C1 RHSMGLCDPGODHW-UHFFFAOYSA-N 0.000 description 2
- RMNIXRMFHYBQQB-UHFFFAOYSA-N 1-[3-(2-methylbutan-2-yl)-1,2-oxazol-5-yl]-3-(3-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1N=C(C(C)(C)CC)C=C1NC(=O)NC1=CC=CC(SC=2C=CN=CC=2)=C1 RMNIXRMFHYBQQB-UHFFFAOYSA-N 0.000 description 2
- OLAYKASHGVRXIZ-UHFFFAOYSA-N 1-[3-(2-methylbutan-2-yl)-1,2-oxazol-5-yl]-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound O1N=C(C(C)(C)CC)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 OLAYKASHGVRXIZ-UHFFFAOYSA-N 0.000 description 2
- JYGHRSVBJYNRTB-UHFFFAOYSA-N 1-[3-(2-methylbutan-2-yl)-1,2-oxazol-5-yl]-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1N=C(C(C)(C)CC)C=C1NC(=O)NC(C=C1)=CC=C1SC1=CC=NC=C1 JYGHRSVBJYNRTB-UHFFFAOYSA-N 0.000 description 2
- JBQPNUNIDPHVFQ-UHFFFAOYSA-N 1-[3-(2-methylbutan-2-yl)-1,2-oxazol-5-yl]-3-[4-(4-methylphenoxy)phenyl]urea Chemical compound O1N=C(C(C)(C)CC)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=C(C)C=C1 JBQPNUNIDPHVFQ-UHFFFAOYSA-N 0.000 description 2
- GCBVDYBTNTVVOV-UHFFFAOYSA-N 1-[3-(3-methylpentan-3-yl)-1,2-oxazol-5-yl]-3-(3-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1N=C(C(C)(CC)CC)C=C1NC(=O)NC1=CC=CC(SC=2C=CN=CC=2)=C1 GCBVDYBTNTVVOV-UHFFFAOYSA-N 0.000 description 2
- HCQRNJBKBZFSAB-UHFFFAOYSA-N 1-[3-(3-methylpentan-3-yl)-1,2-oxazol-5-yl]-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound O1N=C(C(C)(CC)CC)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 HCQRNJBKBZFSAB-UHFFFAOYSA-N 0.000 description 2
- VZQCQRSYTUIZKV-UHFFFAOYSA-N 1-[4-(4-acetylphenoxy)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound C1=CC(C(=O)C)=CC=C1OC(C=C1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 VZQCQRSYTUIZKV-UHFFFAOYSA-N 0.000 description 2
- JTOAETRLMJYYMY-UHFFFAOYSA-N 1-[4-(7ah-1,3-benzodioxol-3a-yloxy)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC34C(OCO3)C=CC=C4)=CC=2)=N1 JTOAETRLMJYYMY-UHFFFAOYSA-N 0.000 description 2
- WGTGBBYSTFTSFN-UHFFFAOYSA-N 3-[3-[(5-tert-butyl-1h-pyrazol-3-yl)carbamoylamino]phenoxy]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(OC=2C=C(NC(=O)NC=3NN=C(C=3)C(C)(C)C)C=CC=2)=C1 WGTGBBYSTFTSFN-UHFFFAOYSA-N 0.000 description 2
- YRVHIOAIPPJICO-UHFFFAOYSA-N 3-[4-[(5-tert-butyl-1,2-oxazol-3-yl)carbamoylamino]phenyl]sulfanyl-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(SC=2C=CC(NC(=O)NC3=NOC(=C3)C(C)(C)C)=CC=2)=C1 YRVHIOAIPPJICO-UHFFFAOYSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99634397A | 1997-12-22 | 1997-12-22 | |
| US08/996,343 | 1997-12-22 | ||
| PCT/US1998/026078 WO1999032106A1 (en) | 1997-12-22 | 1998-12-22 | Inhibition of raf kinase using substituted heterocyclic ureas |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009237917A Division JP2010065042A (ja) | 1997-12-22 | 2009-10-15 | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
| JP2009237895A Division JP2010065041A (ja) | 1997-12-22 | 2009-10-15 | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001526220A JP2001526220A (ja) | 2001-12-18 |
| JP2001526220A5 true JP2001526220A5 (https=) | 2006-01-05 |
| JP4437270B2 JP4437270B2 (ja) | 2010-03-24 |
Family
ID=25542800
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000525097A Expired - Fee Related JP4437270B2 (ja) | 1997-12-22 | 1998-12-22 | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
| JP2009237895A Pending JP2010065041A (ja) | 1997-12-22 | 2009-10-15 | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
| JP2009237917A Pending JP2010065042A (ja) | 1997-12-22 | 2009-10-15 | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009237895A Pending JP2010065041A (ja) | 1997-12-22 | 2009-10-15 | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
| JP2009237917A Pending JP2010065042A (ja) | 1997-12-22 | 2009-10-15 | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1047418B1 (https=) |
| JP (3) | JP4437270B2 (https=) |
| KR (1) | KR100571588B1 (https=) |
| CN (2) | CN100360507C (https=) |
| AT (1) | ATE300299T1 (https=) |
| AU (1) | AU2198999A (https=) |
| BG (1) | BG64984B1 (https=) |
| BR (1) | BR9814374B1 (https=) |
| CA (1) | CA2315717C (https=) |
| CU (1) | CU23126A3 (https=) |
| CZ (1) | CZ299156B6 (https=) |
| DE (2) | DE1047418T1 (https=) |
| DK (1) | DK1047418T3 (https=) |
| ES (1) | ES2153340T3 (https=) |
| GR (1) | GR20010300007T1 (https=) |
| HU (1) | HUP0101704A3 (https=) |
| ID (1) | ID26620A (https=) |
| IL (2) | IL136767A0 (https=) |
| NO (1) | NO326150B1 (https=) |
| NZ (1) | NZ505844A (https=) |
| PL (1) | PL205321B1 (https=) |
| RU (1) | RU2232015C2 (https=) |
| SK (1) | SK286213B6 (https=) |
| TR (1) | TR200002618T2 (https=) |
| UA (1) | UA71904C2 (https=) |
| WO (1) | WO1999032106A1 (https=) |
Families Citing this family (159)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998052558A1 (en) * | 1997-05-23 | 1998-11-26 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS |
| US6291425B1 (en) * | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| BR9814375A (pt) * | 1997-12-22 | 2002-05-21 | Bayer Ag | Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas |
| MXPA00006233A (es) * | 1997-12-22 | 2002-09-18 | Bayer Ag | Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas. |
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| MXPA01008440A (es) | 1999-02-22 | 2002-04-24 | Boehringer Ingelheim Pharma | Derivados heterociclicos policiclos como agentes anti-inflamatorios.. |
| WO2000051998A1 (en) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
| NZ528846A (en) | 1999-03-12 | 2005-05-27 | Boehringer Ingelheim Pharma | Compounds useful as anti-inflammatory agents |
| WO2000055152A1 (en) * | 1999-03-12 | 2000-09-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
| ATE312823T1 (de) | 1999-07-09 | 2005-12-15 | Boehringer Ingelheim Pharma | Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| WO2001036403A1 (en) * | 1999-11-16 | 2001-05-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Urea derivatives as anti-inflammatory agents |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| FR2812633A1 (fr) * | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
| US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| US20020173507A1 (en) * | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| IL154016A0 (en) * | 2000-08-31 | 2003-07-31 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| DE60137273D1 (de) | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| AU2002232439A1 (en) | 2000-11-29 | 2002-06-11 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| CA2443950C (en) * | 2001-04-20 | 2011-10-18 | Bayer Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| EP1652847B1 (en) * | 2001-04-27 | 2008-05-28 | Kirin Pharma Kabushiki Kaisha | Quinoline and quinazoline derivatives for the treatment of tumors |
| WO2002092576A1 (en) | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
| EP1395561A1 (en) | 2001-05-25 | 2004-03-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
| WO2003007955A2 (en) * | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| JP4982685B2 (ja) * | 2001-12-03 | 2012-07-25 | バイエル、ファーマシューテイカルズ、コーポレイション | ヒトがんを処置するための他の細胞毒剤又は細胞増殖抑制剤と組合わせたアリール尿素化合物 |
| NZ532780A (en) | 2001-12-21 | 2006-10-27 | Wellcome Trust | Isolated naturally occurring mutant human B-Raf polypeptides and nucleic acids encoding them |
| US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| MXPA04007830A (es) | 2002-02-11 | 2005-07-01 | Bayer Pharmaceuticals Corp | Arilureas como inhibidores de cinasa. |
| US20040023961A1 (en) * | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
| ATE386030T1 (de) | 2002-02-25 | 2008-03-15 | Boehringer Ingelheim Pharma | 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen |
| TWI314928B (en) | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
| RU2340605C2 (ru) | 2002-06-27 | 2008-12-10 | Ново Нордиск А/С | Арилкарбонильные производные в качестве терапевтических средств |
| BR0312023A (pt) | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica |
| JP3763414B2 (ja) | 2002-10-21 | 2006-04-05 | 麒麟麦酒株式会社 | Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形 |
| EP2426122A1 (en) * | 2002-10-24 | 2012-03-07 | Merck Patent GmbH | Methylene urea derivative as RAF kinasse inhibitors |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| CA2511970C (en) | 2003-01-14 | 2012-06-26 | Cytokinetics, Inc. | Urea derivatives useful in the treatment of heart failure |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| EP1608639A2 (en) | 2003-02-28 | 2005-12-28 | Bayer Pharmaceuticals Corporation | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
| DE602004030222D1 (de) * | 2003-02-28 | 2011-01-05 | Bayer Healthcare Llc | 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen |
| CA2520009A1 (en) * | 2003-03-24 | 2004-10-07 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Oxamide derivatives useful as raf-kinase inhibitors |
| WO2004085433A2 (en) * | 2003-03-28 | 2004-10-07 | Pharmacia & Upjohn Company Llc | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| MXPA05012377A (es) | 2003-05-15 | 2006-05-25 | Arqule Inc | Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38. |
| WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| CA2531485C (en) * | 2003-07-07 | 2013-03-26 | Merck Patent Gmbh | Malonamide derivatives |
| EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
| US20050192314A1 (en) | 2003-11-13 | 2005-09-01 | Ambit Biosciences Corporation | Urea derivatives as C-kit modulators |
| JP4834840B2 (ja) | 2004-01-06 | 2011-12-14 | ノヴォ ノルディスク アー／エス | ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用 |
| TW200530236A (en) | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| JP2007532615A (ja) * | 2004-04-13 | 2007-11-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| CN101010315A (zh) | 2004-04-30 | 2007-08-01 | 拜耳制药公司 | 用于治疗癌症的取代的吡唑基脲衍生物 |
| WO2005113534A2 (en) * | 2004-05-12 | 2005-12-01 | Schering Corporation | Cxcr1 and cxcr2 chemokine antagonists |
| ATE460402T1 (de) * | 2004-05-12 | 2010-03-15 | Bristol Myers Squibb Co | Für die behandlung von thrombotischen leiden geeignete harnstoffantagonisten des p2y1- rezeptors |
| JP5080970B2 (ja) | 2004-06-17 | 2012-11-21 | サイトキネティクス・インコーポレーテッド | 心疾患を治療するための置換尿素誘導体 |
| WO2006010082A1 (en) | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
| PL1778686T3 (pl) | 2004-08-12 | 2009-04-30 | Pfizer | Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38 |
| MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| AU2005283422C1 (en) | 2004-09-17 | 2017-02-02 | Eisai R & D Management Co., Ltd. | Medicinal composition |
| EP1645556A1 (en) * | 2004-10-07 | 2006-04-12 | Boehringer Ingelheim International GmbH | Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents |
| JP2008517064A (ja) | 2004-10-19 | 2008-05-22 | アークル インコーポレイテッド | Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成 |
| RU2402544C2 (ru) * | 2005-01-14 | 2010-10-27 | Си Джи Ай ФАРМАСЬЮТИКАЛЗ, ИНК. | 1,3-диарилзамещенные мочевины как модуляторы киназной активности |
| WO2006076592A1 (en) | 2005-01-14 | 2006-07-20 | Cgi Pharmaceuticals, Inc. | 1,3 substituted diaryl ureas as modulators of kinase activity |
| SG160364A1 (en) | 2005-03-07 | 2010-04-29 | Bayer Schering Pharma Ag | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer |
| DE102005015253A1 (de) | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | Pyrazolderivate |
| WO2007024294A2 (en) | 2005-05-03 | 2007-03-01 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
| WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| JP5072595B2 (ja) | 2005-08-05 | 2012-11-14 | 中外製薬株式会社 | マルチキナーゼ阻害剤 |
| DE102005037499A1 (de) * | 2005-08-09 | 2007-02-15 | Merck Patent Gmbh | Pyrazolderivate |
| EP1960394A2 (en) * | 2005-11-15 | 2008-08-27 | Bayer HealthCare AG | Pyrazolyl urea derivatives useful in the treatment of cancer |
| JP2009518298A (ja) * | 2005-12-01 | 2009-05-07 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療に有用な尿素化合物 |
| TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| EP1962852B1 (en) | 2005-12-19 | 2017-01-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US8580798B2 (en) | 2005-12-21 | 2013-11-12 | Bayer Intellectual Property Gmbh | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| WO2007076460A2 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Substituted thiazole ureas useful as inhibitors of protein kinases |
| ES2422890T3 (es) | 2006-03-17 | 2013-09-16 | Ambit Biosciences Corporation | Compuestos de imidazolotiazol para el tratamiento de enfermedades proliferativas |
| PE20080359A1 (es) | 2006-04-19 | 2008-06-06 | Novartis Ag | Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r |
| RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| US20080045589A1 (en) | 2006-05-26 | 2008-02-21 | Susan Kelley | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer |
| DE102006029795A1 (de) * | 2006-06-27 | 2008-01-03 | Schebo Biotech Ag | Neue Harnstoff-Derivate und deren Verwendungen |
| CN101511793B (zh) | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| WO2008076883A2 (en) | 2006-12-15 | 2008-06-26 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
| JP2010514692A (ja) | 2006-12-20 | 2010-05-06 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物 |
| CN101600694A (zh) | 2007-01-29 | 2009-12-09 | 卫材R&D管理有限公司 | 未分化型胃癌治疗用组合物 |
| KR20100014811A (ko) * | 2007-04-20 | 2010-02-11 | 데시페라 파마슈티칼스, 엘엘씨. | 골수증식성 질환 및 기타 증식성 질환의 치료에 유용한 키나제 억제제 |
| WO2008153947A2 (en) | 2007-06-07 | 2008-12-18 | Amgen Inc. | Heterocyclic compounds as raf kinase modulators |
| CA2696776C (en) | 2007-09-19 | 2015-12-15 | Ambit Biosciences Corporation | Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| PE20091561A1 (es) | 2008-02-29 | 2009-10-30 | Array Biopharma Inc | Compuestos inhibidores de raf y metodos para su uso |
| JP2011513331A (ja) | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤 |
| MY159230A (en) * | 2008-10-02 | 2016-12-30 | Respivert Ltd | P38 map kinase inhibitors |
| JP5670912B2 (ja) * | 2008-12-11 | 2015-02-18 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| KR101739994B1 (ko) | 2009-04-03 | 2017-05-25 | 에프. 호프만-라 로슈 아게 | 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도 |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| KR101457027B1 (ko) | 2009-06-09 | 2014-10-31 | 캘리포니아 캐피탈 에쿼티, 엘엘씨 | 트리아진 유도체와 이들의 치료적 용도 |
| WO2010144394A1 (en) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
| DK2468281T3 (en) | 2009-08-19 | 2016-03-21 | Eisai R&D Man Co Ltd | Quinolinderivatholdig pharmaceutical composition |
| NZ599866A (en) | 2009-11-06 | 2014-09-26 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2011124923A2 (en) * | 2010-04-08 | 2011-10-13 | Respivert Limited | Novel compounds |
| WO2011162343A1 (ja) | 2010-06-25 | 2011-12-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤 |
| WO2012008564A1 (ja) * | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | 含窒素芳香族複素環誘導体 |
| KR20130091331A (ko) | 2010-07-16 | 2013-08-16 | 교와 핫꼬 기린 가부시키가이샤 | 함질소 방향족 복소환 유도체 |
| CA2805874A1 (en) | 2010-07-19 | 2012-01-26 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| KR101911972B1 (ko) * | 2011-02-07 | 2018-10-25 | 플렉시콘 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| WO2014015056A2 (en) * | 2012-07-17 | 2014-01-23 | Washington University | Anti-mucus drugs and uses therefor |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| EP2997377B1 (en) | 2013-05-14 | 2018-07-18 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| US9750723B2 (en) | 2013-10-31 | 2017-09-05 | Ohio University | Prevention and treatment of non-alcoholic fatty liver disease |
| WO2016010609A1 (en) | 2014-07-18 | 2016-01-21 | Ohio University | Prevention and treatment of non-alcoholic fatty liver disease |
| CA2957785C (en) | 2014-08-11 | 2023-01-03 | Angion Biomedica Corporation | Cytochrome p450 inhibitors and uses thereof |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| PE20170705A1 (es) | 2014-09-10 | 2017-05-21 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) |
| EA032030B1 (ru) | 2014-09-10 | 2019-03-29 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы |
| US9638690B2 (en) | 2014-11-07 | 2017-05-02 | The University Of British Columbia | Compounds and compositions for use as alkylating agent sensors and methods of use thereof |
| JP2018501279A (ja) | 2014-12-31 | 2018-01-18 | アンギオン バイオメディカ コーポレイション | 疾患を治療するための方法及び薬剤 |
| AU2016224583B2 (en) | 2015-02-25 | 2021-06-03 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| EP3500257B1 (en) * | 2016-08-17 | 2025-07-02 | Icahn School of Medicine at Mount Sinai | Kinase inhibitor compounds, compositions, and methods of treating cancer |
| CN106866571B (zh) * | 2017-01-20 | 2018-06-29 | 中国药科大学 | 杂环脲类化合物及其药物组合物和应用 |
| JP6581320B2 (ja) | 2017-02-08 | 2019-09-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| EP3624800A4 (en) | 2017-05-16 | 2021-02-17 | Eisai R&D Management Co., Ltd. | TREATMENT OF HEPATOCELLULAR CARCINOMA |
| KR102708177B1 (ko) | 2018-01-31 | 2024-09-23 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| CN112040945A (zh) | 2018-06-12 | 2020-12-04 | Vtv治疗有限责任公司 | 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 |
| CN110903245B (zh) * | 2018-09-17 | 2022-11-22 | 南京药石科技股份有限公司 | 一种合成1-烷基-2-三氟甲基-5-氨基-1h-咪唑的关键中间体及其制备方法 |
| EP3938363A1 (en) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| KR20220038696A (ko) * | 2019-07-19 | 2022-03-29 | 아나제네시스 바이오테크놀로지스 에스.에이.에스. | 폴리방향족 우레아 유도체 및 근육 질환 치료에서의 이들의 용도 |
| LT4013412T (lt) | 2019-08-12 | 2026-03-25 | Deciphera Pharmaceuticals, Llc | Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui |
| PT4013412T (pt) | 2019-08-12 | 2026-03-18 | Deciphera Pharmaceuticals Llc | Ripretinib para o tratamento de tumores estromais gastrointestinais |
| HRP20231699T1 (hr) | 2019-12-30 | 2024-05-10 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primjene |
| CN115243681B (zh) | 2019-12-30 | 2024-08-16 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| WO2021180008A1 (zh) * | 2020-03-11 | 2021-09-16 | 暨南大学 | 含脲结构的三芳环化合物及其应用 |
| WO2022135442A1 (zh) * | 2020-12-22 | 2022-06-30 | 上海拓界生物医药科技有限公司 | Cdk2抑制剂及其制备方法 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| WO2024126777A1 (en) * | 2022-12-16 | 2024-06-20 | Astrazeneca Ab | Heteroaromatic compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3754887A (en) * | 1969-05-05 | 1973-08-28 | Du Pont | Ureidopyrazoles defoliants |
| JPS5031039A (https=) * | 1973-07-27 | 1975-03-27 | ||
| US3990879A (en) * | 1974-12-26 | 1976-11-09 | Eli Lilly And Company | Method of controlling aquatic weeds |
| US4183854A (en) * | 1976-11-10 | 1980-01-15 | John Wyeth & Brother Limited | Thiazole compound |
| US4042372A (en) * | 1976-11-19 | 1977-08-16 | Eli Lilly And Company | Substituted thiadiazolotriazinediones and method of preparation |
| JPS5386033A (en) * | 1977-10-20 | 1978-07-29 | Shionogi & Co Ltd | Herbicides |
| DE3612830A1 (de) * | 1986-04-16 | 1987-10-22 | Basf Ag | Thiadiazolylharnstoff enthaltendes mittel zur entblaetterung von pflanzen |
| FR2639636B1 (fr) * | 1988-11-30 | 1994-03-04 | Novapharme | Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant |
| GB9000644D0 (en) * | 1990-01-11 | 1990-03-14 | Erba Carlo Spa | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
| KR930702334A (ko) * | 1990-09-13 | 1993-09-08 | 데이비드 로버트 | 5 하이드록시트립타민 수용체 길항제로서의 인돌우레아 |
| US5185358A (en) * | 1991-06-24 | 1993-02-09 | Warner-Lambert Co. | 3-heteroatom containing urea and thiourea ACAT inhibitors |
| US5162360A (en) * | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
| EP0630373A1 (en) * | 1992-03-12 | 1994-12-28 | Smithkline Beecham Plc | Indole derivatives as 5ht1c antagonists |
| WO1994014801A1 (en) * | 1992-12-29 | 1994-07-07 | Smithkline Beecham Plc | Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists |
| EP0784612A1 (en) * | 1994-10-04 | 1997-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
| EP0809492A4 (en) * | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| US5814646A (en) * | 1995-03-02 | 1998-09-29 | Eli Lilly And Company | Inhibitors of amyloid beta-protein production |
| US5773459A (en) * | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
| CA2252465C (en) * | 1996-04-23 | 2007-07-03 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of impdh enzyme |
| GB9623833D0 (en) * | 1996-11-16 | 1997-01-08 | Zeneca Ltd | Chemical compound |
| ATE399007T1 (de) * | 1997-05-23 | 2008-07-15 | Bayer Pharmaceuticals Corp | Raf kinase hemmer |
| GB9723789D0 (en) * | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
| ID26328A (id) * | 1997-12-22 | 2000-12-14 | Bayer Ag | Penghambat raf kinase menggunakan urea heterosiklik tersubstitusi aril dan heteroaril |
| MXPA00006233A (es) * | 1997-12-22 | 2002-09-18 | Bayer Ag | Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas. |
-
1998
- 1998-12-22 SK SK963-2000A patent/SK286213B6/sk not_active IP Right Cessation
- 1998-12-22 EP EP98965981A patent/EP1047418B1/en not_active Expired - Lifetime
- 1998-12-22 ID IDW20001429A patent/ID26620A/id unknown
- 1998-12-22 UA UA2000074352A patent/UA71904C2/uk unknown
- 1998-12-22 HU HU0101704A patent/HUP0101704A3/hu unknown
- 1998-12-22 DE DE1047418T patent/DE1047418T1/de active Pending
- 1998-12-22 KR KR1020007006929A patent/KR100571588B1/ko not_active Expired - Fee Related
- 1998-12-22 CN CNB2004100286556A patent/CN100360507C/zh not_active Expired - Fee Related
- 1998-12-22 NZ NZ505844A patent/NZ505844A/en not_active IP Right Cessation
- 1998-12-22 BR BRPI9814374-3B1A patent/BR9814374B1/pt not_active IP Right Cessation
- 1998-12-22 AT AT98965981T patent/ATE300299T1/de active
- 1998-12-22 RU RU2000120184/15A patent/RU2232015C2/ru not_active IP Right Cessation
- 1998-12-22 DK DK98965981T patent/DK1047418T3/da active
- 1998-12-22 IL IL13676798A patent/IL136767A0/xx active IP Right Grant
- 1998-12-22 CZ CZ20002350A patent/CZ299156B6/cs not_active IP Right Cessation
- 1998-12-22 AU AU21989/99A patent/AU2198999A/en not_active Abandoned
- 1998-12-22 DE DE69831013T patent/DE69831013T2/de not_active Expired - Lifetime
- 1998-12-22 JP JP2000525097A patent/JP4437270B2/ja not_active Expired - Fee Related
- 1998-12-22 WO PCT/US1998/026078 patent/WO1999032106A1/en not_active Ceased
- 1998-12-22 ES ES98965981T patent/ES2153340T3/es not_active Expired - Lifetime
- 1998-12-22 CN CNB988136236A patent/CN1149085C/zh not_active Expired - Fee Related
- 1998-12-22 PL PL343083A patent/PL205321B1/pl not_active IP Right Cessation
- 1998-12-22 CA CA2315717A patent/CA2315717C/en not_active Expired - Fee Related
- 1998-12-22 TR TR2000/02618T patent/TR200002618T2/xx unknown
-
2000
- 2000-06-14 IL IL136767A patent/IL136767A/en not_active IP Right Cessation
- 2000-06-21 NO NO20003232A patent/NO326150B1/no not_active IP Right Cessation
- 2000-06-22 CU CU154A patent/CU23126A3/es not_active IP Right Cessation
- 2000-07-12 BG BG104597A patent/BG64984B1/bg unknown
-
2001
- 2001-02-28 GR GR20010300007T patent/GR20010300007T1/el unknown
-
2009
- 2009-10-15 JP JP2009237895A patent/JP2010065041A/ja active Pending
- 2009-10-15 JP JP2009237917A patent/JP2010065042A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001526220A5 (https=) | ||
| CA2315717A1 (en) | Inhibition of raf kinase using substituted heterocyclic ureas | |
| RU2000120184A (ru) | Способ подавления роста опухолевых клеток, опосредованного киназой raf, гетероциклические производные мочевины (варианты), фармацевтическая композиция (варианты) | |
| JP2004506718A5 (https=) | ||
| KR930005992A (ko) | 루코트리엔 생합성 억제제 | |
| JP2004504301A5 (https=) | ||
| CA2418868A1 (en) | 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists | |
| RU2003105805A (ru) | Производные 4-фенилпиридина в качестве антагонистов рецепторов нейрокинина-1 | |
| JP2001526269A5 (https=) | ||
| CA2404125A1 (en) | Sulphonamido-substituted bridged bicycloalkyl derivatives | |
| JP2007502264A5 (https=) | ||
| JP2003526613A5 (https=) | ||
| US6313153B1 (en) | Compositions and methods for treating nephritis and inhibiting TGF -β related conditions using pyridylacrylamide derivatives | |
| RU2004117887A (ru) | Ариланилиновые агонисты бета2 адренергических рецепторов | |
| JP2005509024A5 (https=) | ||
| KR20060066711A (ko) | 칼슘이온-방출-활성화-칼슘이온 채널을 조절하는 방법 | |
| JP2007504284A5 (https=) | ||
| RU2007124187A (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
| CA2536954A1 (en) | C-kit modulators and methods of use | |
| SI9210092B (en) | N-phenylcarbamate compound, procedure for its preparation and biocidal composition for pest control | |
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2007501831A5 (https=) | ||
| JPH0386864A (ja) | 強心剤 | |
| JP2006525990A5 (https=) | ||
| JP2005519885A5 (https=) |